MCID: SCN001
MIFTS: 38

Secondary Hyperparathyroidism of Renal Origin malady

Categories: Endocrine diseases, Nephrological diseases

Aliases & Classifications for Secondary Hyperparathyroidism of Renal Origin

Aliases & Descriptions for Secondary Hyperparathyroidism of Renal Origin:

Name: Secondary Hyperparathyroidism of Renal Origin 12
Hyperparathyroidism, Secondary 42 69
Secondary Hyperparathyroidism 12 14
Hyperparathyroidism Due to Renal Insufficiency 12
Secondary Hyperparathyroidism Nos 12
Hyperparathyroidism Secondary 52

Classifications:



External Ids:

Disease Ontology 12 DOID:12465 DOID:12466
ICD10 33 N25.81 E21.1
ICD9CM 35 588.81
MeSH 42 D006962
NCIt 47 C113335

Summaries for Secondary Hyperparathyroidism of Renal Origin

MalaCards based summary : Secondary Hyperparathyroidism of Renal Origin, also known as hyperparathyroidism, secondary, is related to non-renal secondary hyperparathyroidism and familial chronic myelocytic leukemia-like syndrome. An important gene associated with Secondary Hyperparathyroidism of Renal Origin is PTH (Parathyroid Hormone), and among its related pathways/superpathways are Ca, cAMP and Lipid Signaling and Development_Hedgehog and PTH signaling pathways in bone and cartilage development. The drugs Benzocaine and Sevelamer have been mentioned in the context of this disorder. Affiliated tissues include bone, and related phenotypes are hematopoietic system and endocrine/exocrine gland

Related Diseases for Secondary Hyperparathyroidism of Renal Origin

Diseases related to Secondary Hyperparathyroidism of Renal Origin via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 75)
id Related Disease Score Top Affiliating Genes
1 non-renal secondary hyperparathyroidism 12.0
2 familial chronic myelocytic leukemia-like syndrome 10.3 CASR PTH
3 hypochondrogenesis 10.3 BGLAP PTH
4 deafness, nonsyndromic, modifier 1 10.3 CASR VDR
5 toxicodendron dermatitis 10.3 BGLAP PTH
6 opthalmoplegia mental retardation lingua scrotalis 10.2 FGF23 PTH
7 joubert syndrome 9 10.2 FGF23 PTH
8 osteochondrodysplasia 10.2 PTH VDR
9 obesity, severe bmiq9 10.2 BGLAP PTH
10 achalasia-addisonianism-alacrimia syndrome 10.2 CYP27B1 VDR
11 parathyroid gland disease 10.2 CASR FGF23 PTH
12 atrial heart septal defect 10.1 CALCA PTH
13 mitochondrial dna depletion syndrome 6 10.1 CASR VDR
14 striatonigral degeneration 10.1 ALB CASR PTH
15 prediabetes syndrome 10.1 BGLAP FGF23 PTH
16 high-grade dysplasia in patients with barrett esophagus 10.1 BGLAP CASR VDR
17 opportunistic bacterial infectious disease 10.1 BGLAP FGF23 PTH
18 microcephaly 10, primary, autosomal recessive 10.1 ACP5 TNFRSF11B
19 lipodystrophy, familial partial, type 6 10.1 ACP5 BGLAP
20 endemic goiter 10.1 BGLAP CALCA
21 phka2-related phosphorylase kinase deficiency 10.1 CALCA TNFRSF11B
22 bronchus cancer 10.1 ACP5 TNFRSF11B
23 orbit lymphoma 10.1 CYP27B1 FGF23 PTH
24 bulbomembranous urethral cancer 10.1 ACP5 TNFRSF11B
25 birk-barel mental retardation dysmorphism syndrome 10.1 CALCA TNFRSF11B
26 epilepsy, idiopathic generalized 14 10.1 BGLAP FGF23 TNFRSF11B
27 hypotrichosis 8 10.1 BGLAP PTH TNFRSF11B
28 breast metaplastic carcinoma 10.1 EPO PTH
29 prostate cancer, hereditary, x-linked 2 10.1 CYP27B1 FGF23 VDR
30 epidermolysis bullosa, junctional, herlitz type 10.1 CALCA CASR PTH
31 weill-marchesani syndrome 10.1 CASR FGF23 PTH VDR
32 deafness, autosomal recessive 42 10.0 CALCA CASR VDR
33 toenail dystrophy, isolated 10.0 CALCA FGF23 PTH
34 adult ependymoblastoma 10.0 BGLAP CALCA PTH
35 hypophosphatasia, adult 10.0 BGLAP CALCA PTH
36 myofascial pain syndrome 10.0 ACP5 CALCA
37 listeria meningitis 10.0 CASR TNFRSF11B
38 stickler syndrome 10.0 CALCA PTH TNFRSF11B
39 hemopericardium 10.0 ALB CALCA
40 axial osteomalacia 10.0 BGLAP CALCA FGF23
41 cerebral sarcoidosis 10.0 ALB EPO
42 phacolytic glaucoma 10.0 BGLAP CALCA
43 coffin-lowry syndrome 10.0 CYP27B1 FGF23 PTH VDR
44 y chromosome detection 10.0 BGLAP CYP27B1 PTH VDR
45 ovarian papillary cystadenoma 9.9 ALB EPO
46 waardenburg syndrome, type 4b 9.9 CALCA CASR PTH VDR
47 basal ganglia cerebrovascular disease 9.9 ALB EPO
48 mesenchymal cell neoplasm 9.9 BGLAP CALCA CASR PTH
49 familial nephrotic syndrome 9.9 ALB EPO PTH
50 chromosomal disease 9.9 ACP5 BGLAP PTH TNFRSF11B

Graphical network of the top 20 diseases related to Secondary Hyperparathyroidism of Renal Origin:



Diseases related to Secondary Hyperparathyroidism of Renal Origin

Symptoms & Phenotypes for Secondary Hyperparathyroidism of Renal Origin

MGI Mouse Phenotypes related to Secondary Hyperparathyroidism of Renal Origin:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.87 CASR CYP27B1 EPO FGF23 PTH TNFRSF11B
2 endocrine/exocrine gland MP:0005379 9.85 ALB CASR CYP27B1 FGF23 PTH VDR
3 immune system MP:0005387 9.8 PTH TNFRSF11B VDR CASR CYP27B1 EPO
4 limbs/digits/tail MP:0005371 9.63 CYP27B1 EPO FGF23 PTH TNFRSF11B VDR
5 renal/urinary system MP:0005367 9.35 ALB CASR CYP27B1 FGF23 VDR
6 skeleton MP:0005390 9.17 CASR CYP27B1 EPO FGF23 PTH TNFRSF11B

Drugs & Therapeutics for Secondary Hyperparathyroidism of Renal Origin

Drugs for Secondary Hyperparathyroidism of Renal Origin (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 122)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Benzocaine Approved Phase 4,Phase 3,Phase 2 1994-09-7, 94-09-7 2337
2
Sevelamer Approved Phase 4,Phase 3,Phase 2 52757-95-6, 152751-57-0 3085017
3
Darbepoetin alfa Approved, Investigational Phase 4 11096-26-7, 209810-58-2
4
Calcium acetate Approved Phase 4 62-54-4
5
Calcium carbonate Approved Phase 4,Phase 3,Phase 2 471-34-1
6
Alendronate Approved Phase 4,Phase 2 121268-17-5, 66376-36-1 2088
7
Zoledronic acid Approved Phase 4,Phase 1 118072-93-8 68740
8
Pamidronate Approved Phase 4 40391-99-9 4674
9
Denosumab Approved Phase 4,Phase 1 615258-40-7
10
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
11
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
12
Iron Approved Phase 4 7439-89-6 23925
13
Ergocalciferol Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1 50-14-6 5280793
14 tannic acid Approved, Nutraceutical Phase 4,Phase 3,Phase 2
15
Cholecalciferol Approved, Nutraceutical Phase 4,Phase 3,Phase 2 67-97-0 6221 10883523 5280795
16
Calcitriol Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1 32222-06-3 134070 5280453
17
Alfacalcidol Approved, Nutraceutical Phase 4 41294-56-8 5282181
18
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4 11103-57-4, 68-26-8 445354
19
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
20
Niacin Approved, Investigational, Nutraceutical Phase 4 59-67-6 938
21
Nicotinamide Approved, Nutraceutical Phase 4 98-92-0 936
22 Bone Density Conservation Agents Phase 4,Phase 3,Phase 2,Phase 1
23 Calcimimetic Agents Phase 4,Phase 2,Phase 3,Phase 1
24 Calcium, Dietary Phase 4,Phase 3,Phase 2,Phase 1
25 Cinacalcet Hydrochloride Phase 4,Phase 2,Phase 3,Phase 1
26 Ergocalciferols Phase 4,Phase 3,Phase 2,Phase 1
27 Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1
28 Hormones Phase 4,Phase 2,Phase 3,Phase 1
29 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1
30 Micronutrients Phase 4,Phase 3,Phase 2,Phase 1
31 Trace Elements Phase 4,Phase 3,Phase 2,Phase 1
32 vitamin d Phase 4,Phase 2,Phase 3,Phase 1
33 Vitamins Phase 4,Phase 2,Phase 3,Phase 1
34 1 alpha-hydroxyergocalciferol Phase 4,Phase 3,Phase 2,Phase 1
35 Vasoconstrictor Agents Phase 4,Phase 3,Phase 2,Phase 1
36 Hydroxycholecalciferols Phase 4,Phase 3
37 Calcifediol Phase 4,Phase 3,Phase 1 19356-17-3
38 Pharmaceutical Solutions Phase 4,Phase 2,Phase 3,Phase 1
39 Epoetin alfa Phase 4 113427-24-0
40 Hematinics Phase 4
41 Anticholesteremic Agents Phase 4
42 Antimetabolites Phase 4,Phase 2
43 Atorvastatin Calcium Phase 4 134523-03-8
44 Chelating Agents Phase 4,Phase 3,Phase 2
45 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 4
46 Hypolipidemic Agents Phase 4,Phase 2
47 Lipid Regulating Agents Phase 4,Phase 2
48 Liver Extracts Phase 4
49 Antacids Phase 4,Phase 3,Phase 2
50 Anti-Ulcer Agents Phase 4,Phase 3,Phase 2

Interventional clinical trials:

(show top 50) (show all 218)
id Name Status NCT ID Phase
1 Cinacalcet in Management of Secondary Hyperparathyroidism in Haemodialysis Patients Unknown status NCT02338934 Phase 4
2 Characterization of Hyperparathyroidism and Vitamin D Deficiency in Obesity Unknown status NCT00288873 Phase 4
3 How Bone is Made in Children Receiving Dialysis Unknown status NCT01799317 Phase 4
4 Anti-proteinuric Effect of Calcitriol in Non-diabetic Kidney Disease Patients Unknown status NCT01512862 Phase 4
5 Compare the Efficacy of Cinacalcet vs Traditional Vitamin D for Secondary Hyperparathyroidism (SHPT) Among Subjects Undergoing Hemodialysis Completed NCT01181531 Phase 4
6 Initial Dosing of Paricalcitol in Secondary Hyperparathyroidism Completed NCT00307840 Phase 4
7 Parathyroidectomy vs Cinacalcet in the Treatment of Secondary Hyperparathyroidism Post Renal Transplantation Completed NCT01178450 Phase 4
8 ACHIEVE: Optimizing the Treatment of Secondary Hyperparathyroidism Completed NCT00135304 Phase 4
9 Efficacy and Safety of 6 Months Treatment With Paricalcitol Injection or Oral in Patients With Secondary Hyperparathyroidism on Dialysis Completed NCT00537979 Phase 4
10 Efficacy and Safety of Alfacalcidol Compared to Calcitriol for Treatment of Secondary Hyperparathyroidism Completed NCT01115543 Phase 4
11 Paricalcitol Versus Calcitriol for Efficacy and Safety in Stage 3/4 Chronic Kidney Disease (CKD) With Secondary Hyperparathyroidism (SHPT) Completed NCT00823303 Phase 4
12 START: Sensipar Treatment Algorithm to Reach K/DOQI Targets in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism Completed NCT00132431 Phase 4
13 Efficacy and Safety of Paricalcitol in the Reduction of Secondary Hyperparathyroidism After Kidney Transplantation. Completed NCT01939977 Phase 4
14 Study of Safety and Efficacy of Doxercalciferol in Patients With Chronic Kidney Disease, Stage 3 or 4, and Secondary Hyperparathyroidism Completed NCT00123461 Phase 4
15 Effectiveness and Safety of IV Zemplar in Patients on Hemodialysis and With Secondary Hyperparathyroidism Using iPTH/100 as Initial Dose Completed NCT00891813 Phase 4
16 Cinacalcet stUdy for Peritoneal Dialysis Patients In Double Arm on the Lowing Effect OF iPTH Level Completed NCT01101113 Phase 4
17 A Phase 4 Study to Determine Dosing of Hectorol® Capsules When Converting From Zemplar® Injection Completed NCT00463021 Phase 4
18 Cincalcet and Vascular Arterial Stiffness Among Peritoneal Dialysis Patients With Secondary Hyperparathyroidism Completed NCT01143987 Phase 4
19 20070360 Incident Dialysis Completed NCT00803712 Phase 4
20 A Phase 4, Conversion Study of Hectorol® Injection to Hectorol® Capsules in Stage 5 CKD Patients on Dialysis Completed NCT00418600 Phase 4
21 The Study of Efficacy and Safety of REGPARA Drug in Dialysis Patients Have High Blood Levels of Parathyroid Completed NCT02056730 Phase 4
22 Vitamin D Deficiency in Chronic Kidney Disease (CKD) Patients Completed NCT00958451 Phase 4
23 Study to Evaluate the Effects of Zemplar Injection and Calcijex on Intestinal Absorption of Calcium Completed NCT00073710 Phase 4
24 How Vitamin D Analogues Affect Endothelial Cells in Patients on Dialysis Completed NCT00528788 Phase 4
25 Evaluation of the Effectiveness of Paricalcitol Versus Cinacalcet With Low-Dose Vitamin D Completed NCT00977080 Phase 4
26 Treatment Adhesion in Dialysis Patients Treated With Cinacalcet Completed NCT01573520 Phase 4
27 A Phase 4 Pharmacokinetic Study of Hectorol Injection and Zemplar Injection in CKD Subjects on Hemodialysis Completed NCT00454350 Phase 4
28 A Pilot Clinical Study Evaluating the Effect of Parathyroid Hormone (PTH) Lowering On Erythropoietin Consumption in Calcitriol-Resistant Patients Completed NCT01506947 Phase 4
29 A Study of Cinacalcet to Improve Achievement of National Kidney Foundation Kidney Disease Outcomes Quality Initiative (K/DOQI) Targets in Patients With End Stage Renal Disease (ESRD) Completed NCT00431496 Phase 4
30 Trial to Optimize Mineral Outcomes in Dialysis Patients Completed NCT01100723 Phase 4
31 Safety and Effectiveness of Zemplar Injection in Decreasing iPTH Levels in Pediatric ESRD Subjects on Hemodialysis Completed NCT00053547 Phase 4
32 A Study of Zemplar® Injection and Hectorol® Injection on Intestinal Absorption of Calcium in Chronic Kidney Disease Completed NCT00257920 Phase 4
33 CARE-2 (Calcium Acetate [PhosLo®]/Sevelamer[Renagel®] Evaluation Study 2) for Heart Calcification in Dialysis Patients Completed NCT00211939 Phase 4
34 A Research Study for Patients With End-Stage Renal Disease (ESRD) Completed NCT00110890 Phase 4
35 Paricalcitol Effect on Anemia in CKD Completed NCT01768351 Phase 4
36 Vitamin D Status in Males in Jerusalem Area and Its Correlation to Parathyroid Hormone (PTH) Level and Bone Mineral Density Completed NCT01025128 Phase 4
37 Vitamin D and Coronary Calcification Study Completed NCT00752102 Phase 4
38 Effect of Phosphate Binders on FGF-23 With Concurrent Calcitriol Completed NCT01748396 Phase 4
39 Calcitriol in the Treatment of Immunoglobulin A (IgA) Nephropathy Completed NCT00319761 Phase 4
40 Study of the Effect of Alendronate on Vascular Calcification and Arterial Stiffness in Chronic Kidney Disease Completed NCT00395382 Phase 4
41 Efficacy of Vitamin D2 to Treat Chronic Kidney Disease Mineral and Bone Disorder Completed NCT01633853 Phase 4
42 ADVANCE: Study to Evaluate Cinacalcet Plus Low Dose Vitamin D on Vascular Calcification in Subjects With Chronic Kidney Disease Receiving Hemodialysis Completed NCT00379899 Phase 4
43 Zoledronic Acid to Prevent Bone Loss After Kidney Transplantation Completed NCT01675089 Phase 4
44 Osteopenia and Renal Osteodystrophy: Evaluation and Management Completed NCT00108394 Phase 4
45 Denosumab in Primary Hyperparathyroidism Completed NCT01558115 Phase 4
46 Cholecalciferol Supplementation in Restless Leg Syndrome in Patients With Chronic Kidney Disease Recruiting NCT03063190 Phase 4
47 Physiologic Interactions Between the Adrenal- and the Parathyroid Glands Recruiting NCT02572960 Phase 4
48 Paricalcitol Improves Anemia of Inflammation Recruiting NCT02876211 Phase 4
49 Efficacy of Usual Vitamin D Supplementation and Its Impact on Children and Adolescents Calciuria. Recruiting NCT02238418 Phase 4
50 Intravenous Paricalcitol in Chronic Hemodialysis Patients Active, not recruiting NCT03023748 Phase 4

Search NIH Clinical Center for Secondary Hyperparathyroidism of Renal Origin

Cochrane evidence based reviews: hyperparathyroidism, secondary

Genetic Tests for Secondary Hyperparathyroidism of Renal Origin

Anatomical Context for Secondary Hyperparathyroidism of Renal Origin

MalaCards organs/tissues related to Secondary Hyperparathyroidism of Renal Origin:

39
Bone

Publications for Secondary Hyperparathyroidism of Renal Origin

Articles related to Secondary Hyperparathyroidism of Renal Origin:

id Title Authors Year
1
Postoperative hungry bone syndrome in patients with secondary hyperparathyroidism of renal origin. ( 22399154 )
2012

Variations for Secondary Hyperparathyroidism of Renal Origin

Expression for Secondary Hyperparathyroidism of Renal Origin

Search GEO for disease gene expression data for Secondary Hyperparathyroidism of Renal Origin.

Pathways for Secondary Hyperparathyroidism of Renal Origin

GO Terms for Secondary Hyperparathyroidism of Renal Origin

Cellular components related to Secondary Hyperparathyroidism of Renal Origin according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.5 ALB BGLAP CALCA EPO FGF23 PTH
2 extracellular space GO:0005615 9.17 ALB BGLAP CALCA EPO FGF23 PTH

Biological processes related to Secondary Hyperparathyroidism of Renal Origin according to GeneCards Suite gene sharing:

(show all 28)
id Name GO ID Score Top Affiliating Genes
1 cellular protein metabolic process GO:0044267 9.79 ALB CALCA FGF23
2 aging GO:0007568 9.78 BGLAP CALCA EPO
3 response to lipopolysaccharide GO:0032496 9.76 ACP5 CYP27B1 EPO TNFRSF11B
4 calcium ion transport GO:0006816 9.75 CASR CYP27B1 VDR
5 skeletal system development GO:0001501 9.71 BGLAP PTH TNFRSF11B VDR
6 positive regulation of cAMP biosynthetic process GO:0030819 9.64 CALCA PTH
7 embryo implantation GO:0007566 9.63 CALCA EPO
8 adenylate cyclase-activating G-protein coupled receptor signaling pathway GO:0007189 9.63 CALCA PTH
9 response to testosterone GO:0033574 9.62 BGLAP EPO
10 bone mineralization GO:0030282 9.61 BGLAP CYP27B1
11 vasodilation GO:0042311 9.6 CALCA CASR
12 bone resorption GO:0045453 9.59 ACP5 PTH
13 decidualization GO:0046697 9.58 CYP27B1 VDR
14 positive regulation of ossification GO:0045778 9.57 CALCA PTH
15 response to inorganic substance GO:0010035 9.56 BGLAP TNFRSF11B
16 cellular calcium ion homeostasis GO:0006874 9.56 CALCA CASR PTH VDR
17 positive regulation of keratinocyte differentiation GO:0045618 9.55 CYP27B1 VDR
18 response to magnesium ion GO:0032026 9.54 FGF23 TNFRSF11B
19 response to vitamin D GO:0033280 9.54 BGLAP CYP27B1 PTH
20 negative regulation of bone resorption GO:0045779 9.52 CALCA TNFRSF11B
21 vitamin D metabolic process GO:0042359 9.51 CYP27B1 FGF23
22 regulation of bone mineralization GO:0030500 9.5 BGLAP CYP27B1 FGF23
23 response to fibroblast growth factor GO:0071774 9.49 CASR PTH
24 negative regulation of calcium ion transport into cytosol GO:0010523 9.48 CALCA EPO
25 response to estrogen GO:0043627 9.46 BGLAP CYP27B1 EPO TNFRSF11B
26 vitamin D catabolic process GO:0042369 9.43 CYP27B1 FGF23
27 cellular response to vitamin D GO:0071305 9.13 BGLAP CASR FGF23
28 positive regulation of vitamin D 24-hydroxylase activity GO:0010980 8.8 CYP27B1 FGF23 VDR

Molecular functions related to Secondary Hyperparathyroidism of Renal Origin according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 hormone activity GO:0005179 8.8 CALCA EPO PTH

Sources for Secondary Hyperparathyroidism of Renal Origin

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....